1、 2015 3 2016 3 , 46 , , -1 -1 , 10 min; 0.05 0 -1 -1 24 h 2 7 d 2 , I (cTnI) N (NT-pro BNT) (NE) C (CRP) (ET-1) ; 2 1 93.5%, 78.3%, 2 =4.389, P=0.036) , 2 LVEDD LVEF SV CO , LVEF SV CO (t=8.489 11.129 6.455, P =0.000) ;2 cTnI NT-pro BNT NE ET-1 CRP , (t=3.033 3.935 29.157 2.478 3.237, P=0.002 0.000
2、0.000 0.008 0.001) ;2 / , (P0.05) ; 1 , , 2 =6.556, P=0.010) , , , , ; ; ; ; ; , E-mail: Effect of levosimendan on advanced heart failure and its effect on related indexes XUAN Bing LI De TANG Bing ZHU Jun Department of Cardiology, General Hospital of Chengdu Military Region; Abstract Objective To i
3、nvestigate the effect of levosimendan on advanced heart failure and its effect on related indexes. Methods Patients with advanced heart failure were selected, which were treated in hospital from March 2015 to March 2017, and they were divided into the observation group ( 46 cases) and control group
4、( 46 cases) . The patients of control group were treated with conventional anti-heart failure treatment. Based on control group, the patients of observation group were treated with levosimendan -1 -1 ) , intravenous injection for 10 min, -1 -1 ) for 24 h) . The patients of 2 groups were all treated
5、for 7 days. Compare the clinical outcomes, the incidence of adverse reactions, follow up 1 year survival rate and changes of the levels of heart function, cTnI, NT-pro BNP, NE, CRP, ET-1 of two groups. Results After the appropriate treatment, the total effective rate of the observation group was 93.
6、 5%, which was significantly higher than 78. 3% of the contr =0. 036) ; The levels of LVEF, SV, CO in the observation group were significantly higher than those in the control group ( t =8. 489, t = 11. 129, t = 6. 455; P = 0. 000, P = 0. 000, P = 0. 000) , while the LVEDD level did not change signi
7、ficantly ( t = 0. 615, P = 0. 269) ; The levels of cTnI, NT-pro BNP, NE, CRP, ET-1 in the observation group were significantly lower than those in the control group ( t = 3. 033, t = 3. 935, t = 29. 157, t = 2. 478, t = 3. 237; P = 0. 002, P = 0. 000, P =0. 000, P = 0. 008, P = 0. 001) ; There were
8、tachycardia, hypotension, hypokalemia, ventricular premature beats, headache, nausea/vomiting and other adverse reactions occurred in both two groups, but the difference between groups was not statistical 2 2 = 2. 2 2 2 2 = 3. 102; P = 0. 269, P = 0. 136, P =0. 466, P = 0. 377, P = 0. 601, P = 0. 07
9、8) ; After the follow up for 1 year, the mortality rate in observation group was 8. 7%, which was s 2 = 6. 556; P = 0. 010) . Conclusion Levosimendan in the treatment of advanced heart failure can obtain the exact effect. It has a significant effect on the improvement of heart function and has a hig
10、h safety, which can improve the prognosis of patients and worthy of clinical promotion. Keyword Levosimendan; Heart failure; Heart function; Related indexes; Survival rate; (heart failure, HF) , , , , 1 2, , , , , , , Ca , ; , , , 3 , , , , , , 1 1.1 2015 3 2016 3 92 , 46 : 29 , 17 ; ; (BMI) 2132 (s
11、ystolic blood pressure, SBP) 134153 (diastolic blood pressure, DBP) 6882 m Hg; /min; (New York Heart Association, NYHA) 22 ; : 31 , 34 , 9 , 23 , 18 , 8 : 27 , 19 ; /min;NYHA 25 ; : 34 , 32 , 11 , 22 , 20 , 9 2 , (P0.05) , , , 1.2 : (1) 4; (2) ; (3) , (left (venous pressure, VP) 16 cm H2O, HR120 /mi
12、n, (pulmonary artery wedge : (1) ; (2) 3 ; (3) ; (4) 6 ; (5) 1.3 , (ACEI) ( ) , 10 min; 24 h 2 7 d, 1.4 (1) 2 Philips5500 (LVEDD) LVEF (SV) (CO) (2) 2 5 ml, Avanti-J26S , 3 000 r/min , , - , ; I (c Tn I) , Access ; N (NT-pro BNP) (NE) ; C (CRP) ; -1 (ET-1) , , (3) 2 (4) 1 2 1.5 5 : , ; : , ; : , = (
13、 + ) / 1.6 SPSS 22.0 (x , t , t ; , , P0.05) , 2 2.3 c Tn I NT-pro BNT NE ET-1 CRP 2 2 , 2 c Tn I NT-pro BNT NE CRP ET-1 (P0.05) , 4 2.5 1 , 4 (8.7%) , 10 (21.7%) , 3 , , 6 7, , , , , , 8, 2% , 5 , , c Tn I , 9 , c Tn I , , 10 , NT-pro BNT , , , (RAAS) , NE ET-1 , , ; , 11, , , TNF CRP , , 3 2 c Tn
14、I NT-pro BNP NE CRP ET-1 4 2 (%) , , C , , , 12-14 15, , , , , 16, , , , , , , , , , 93.5%, 78.3%, , , 17 c T-n I NT-pro BNT NE CRP ET-1 , , , 18 , , , , , 2 / , , , 19 , 1 , , , , , , , , , : : , , ; : , , ; : , , ; : 1 , , , . J. , 2016, 25 (10) :1296-1300.DOI:10.3760/cma.j.issn.1671-0282.2016.10.
15、016. 2 , , , . J. : , 2016, 37 (1) :148-151.DOI:10.7652/jdyxb201601029. 3Dzudie A, Milo O, Edwards C.et al.Prognostic significance of ECG abnormalities for mortality risk in acute heart failure:Insight from the Sub-Saharan Africa survey of heart failure (THESUS-HF) J.J Card Fail, 2014, 20 (1) :45-52
16、.DOI:10.1016/j.cardfail.2013.11.005. 4 , . 2014J. , 2014, 42 (2) :98-122.DOI:10.3760/cma.j.issn.0253-3758.2014.02.004. 5Yang H, Sawyer AM.The Effect of Adaptive servo-ventilation (ASV) on objective and subjective outcomes in cheyne-stokes respiration (CSR) and heart failure (HF) patientsJ.Heart Lung
17、.2016, 45 (3) :199-211.DOI:10.1016/j.hrtlng.2016.02.002. 6Tsukamoto O, Kitakaze M.Different implications of functional tricuspid regurgitation between heart failure (HF) with reduced ejection fraction (EF) and HF with preserved EFJ.Circ J, 2015, 79 (7) :1448-1449.DOI:10.1253/circj.CJ-15-0560. 7Patti
18、ni L, Sassi R, Cerutti S, et al.Dissecting heart failure through the multiscale approach of systems medicineJ.IEEE Trans Biomed Eng, 2014, 61 (5) :1593-1603.DOI:10.1109/TBME.2014.2307758. 8Henriques J, Carvalho P, Paredes S.et al.Prediction of heart failure decompensation events by trend analysis of
19、 telemonitoring dataJ.IEEE J Biomed Health Inform, 2015, 19 (5) :1757-1769.DOI:10.1109/JBHI.2014.2358715. 9 , . I ROC J. , 2015, 35 (11) :2979-2980.DOI:10.3969/j.issn.1005-9202.2015.11.044. 10 , , , . N J. , 2017, 9 (4) :464-466.DOI:10.3969/j.issn.1674-4055.2017.04.22. 11 , , , . J. , 2014, 17 (28) :3363-3367.DOI:10.3969/j.issn.1007-9572.2014.28.021. 12 , , , . J. , 2014, 29 (7) :555-557.DOI:10.3969/j.issn.1000-3614.2014.07.020. 13 , , , .
